The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care

EZ Keung, JE Gershenwald - Expert review of anticancer therapy, 2018 - Taylor & Francis
Introduction: The eighth edition of the American Joint Committee on Cancer (AJCC)
melanoma staging system was implemented in the United States on 1 January 2018. Areas …

Recent advances in the treatment of melanoma

BD Curti, MB Faries - New England Journal of Medicine, 2021 - Mass Medical Soc
Advances in Melanoma Treatment The incidence of melanoma has increased, but mortality
has declined with improved management. Sentinel-node sampling has reduced morbidity …

Neoadjuvant relatlimab and nivolumab in resectable melanoma

RN Amaria, M Postow, EM Burton, MT Tetzlaff, MI Ross… - Nature, 2022 - nature.com
Relatlimab and nivolumab combination immunotherapy improves progression-free survival
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …

Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells

Y Goyal, GT Busch, M Pillai, J Li, RH Boe, EI Grody… - Nature, 2023 - nature.com
Even among genetically identical cancer cells, resistance to therapy frequently emerges
from a small subset of those cells,,,,,–. Molecular differences in rare individual cells in the …

Systemic therapy for melanoma: ASCO guideline update

R Seth, SS Agarwala, H Messersmith… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE To provide guidance to clinicians regarding the use of systemic therapy for
melanoma. METHODS American Society of Clinical Oncology convened an Expert Panel …

B cells and tertiary lymphoid structures promote immunotherapy response

BA Helmink, SM Reddy, J Gao, S Zhang, R Basar… - Nature, 2020 - nature.com
Abstract Treatment with immune checkpoint blockade (ICB) has revolutionized cancer
therapy. Until now, predictive biomarkers,,,,,,,,–and strategies to augment clinical response …

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

RN Amaria, SM Reddy, HA Tawbi, MA Davies… - Nature medicine, 2018 - nature.com
Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is
associated with enhanced survival and antigen-specific T cell responses compared with …

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre …

EA Rozeman, AM Menzies, ACJ van Akkooi… - The lancet …, 2019 - thelancet.com
Background The outcome of patients with macroscopic stage III melanoma is poor.
Neoadjuvant treatment with ipilimumab plus nivolumab at the standard dosing schedule …

Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis

DA Erkes, W Cai, IM Sanchez, TJ Purwin… - Cancer …, 2020 - aacrjournals.org
Combinations of BRAF inhibitors and MEK inhibitors (BRAFi+ MEKi) are FDA-approved to
treat BRAF V600E/K-mutant melanoma. Efficacy of BRAFi+ MEKi associates with cancer cell …

Systemic therapy for melanoma: ASCO guideline

R Seth, H Messersmith, V Kaur, JM Kirkwood… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE To provide guidance to clinicians regarding the use of systemic therapy for
melanoma. METHODS ASCO convened an Expert Panel and conducted a systematic …